Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Michael Roger Harrison

Associate Professor of Medicine
Medicine, Medical Oncology

Selected Grants


Merck LiteSpark-001: Advanced rCC progression after immunotherapy

ResearchPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2022 - 2027

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02

Clinical TrialPrincipal Investigator · Awarded by Propella Therapeutics Inc · 2022 - 2026

ODYSSEY Registry for Renal Cell Carcinoma

ResearchPrincipal Investigator · Awarded by Duke Clinical Research Institute · 2022 - 2026

Title A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (Substudy U03A)

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2026

Merck LiteSpark-001: Advanced rCC progression after immunotherapy

ResearchPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2022 - 2027

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02

Clinical TrialPrincipal Investigator · Awarded by Propella Therapeutics Inc · 2022 - 2026

ODYSSEY Registry for Renal Cell Carcinoma

ResearchPrincipal Investigator · Awarded by Duke Clinical Research Institute · 2022 - 2026

Title A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (Substudy U03A)

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2026

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03):

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2025

Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site

ResearchCo Investigator · Awarded by Department of Defense · 2021 - 2024

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2015 - 2022

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2022

True NTH Project

ResearchCo Investigator · Awarded by Movember Foundation · 2015 - 2021

ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Clinical TrialPrincipal Investigator · Awarded by Clovis Oncology, Inc. · 2018 - 2020

Metastatic Renal Cell Cancer Registry (MaRCC Registry)

ResearchPrincipal Investigator · Awarded by Pfizer, Inc. · 2014 - 2020

A Phase III, open-label, multi-center, randomized study to investigate the efficacy and safety of MPDL3280A

Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2015 - 2020

True NTH Project: Self-Management Portal & Decision Support

ResearchCo Investigator · Awarded by Movember Foundation · 2015 - 2019

Bladder Cancer in Older Adults - Treatment and Outcomes

ResearchCo Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2016 - 2017

RNA Extraction and Amplification from Biopsy Specimens in Subjects with Metastatic Renal Cell Carcinoma

Clinical TrialPrincipal Investigator · Awarded by Argos Therapeutics, Inc. · 2013 - 2017

External Relationships


  • Aveo Oncology
  • Exelixis, Inc.
  • Janssen Oncology
  • Sanofi

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.